Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma

Giuseppe Procopio, Roberto Sabbatini, Camillo Porta, Elena Verzoni, Enzo Galligioni, Cinzia Ortega

Research output: Contribution to journalArticlepeer-review

Abstract

Sequencing decisions in advanced renal cell carcinoma are likely to become more difficult when new targeted agents are approved for first and subsequent lines of therapy. Approximately 70% of patients benefit from targeted therapy before progression, of which 20% can be described as short-term responders (progression-free survival: 6 months). The remaining 30% show either no response (20%) or are intolerant to treatment (10%). The challenge is to establish the optimal second-line agent for over 70% of patients who progress following initial response to a first-line tyrosine kinase inhibitor. As it is impossible to define the optimal second-line therapy for every patient, it is suggested that age and comorbidities of the patient, the sites of disease and the side effects of previous therapies be taken into account in order to optimize the use of different agents sequentially.

Original languageEnglish
Pages (from-to)1089-1096
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2012

Keywords

  • renal cell carcinoma
  • resistance
  • second-and third-line therapy
  • short-and long-term responders
  • sorafenib
  • targeted therapies
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this